Opko Health Inc Dossier
|
SectorHealth Care IndustryDiagnostics & Research Beta (adjusted)1.33 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $1.57Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $1.2B Enterprise Value $873.7M Shares Outstanding 807.5M diluted Moat Rating None Next Earnings Date5 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary OPKO Health is undergoing a significant structural transition, shifting its focus from low-margin diagnostics to high-potential biopharmaceuticals and specialized testing. Following the divestiture of BioReference's oncology assets to Labcorp, the company has successfully narrowed its operating losses and built a robust cash buffer. However, near-term top-line growth remains constrained, and key commercial assets like Rayaldee and NGENLA continue to perform below historical peak expectations. While the pipeline under ModeX Therapeutics offers long-term optionality, the lack of immediate catalysts justifies a Hold rating until diagnostics breakeven is achieved and clinical assets show clear progress. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$3.00 Mean target$4.38 High · most bullish analyst$8.50 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $3.0020% The bear case reflects persistent operating losses in the diagnostics segment due to pricing pressures and volume declines, failing to reach breakeven in 2026. Furthermore, NGENLA sales could plateau due to competitive pressures in the pediatric growth hormone market, and clinical delays or safety signals in the ModeX pipeline could stall development, leading to continued cash burn and eventual capital-raising needs. Base CaseCentral scenario $4.3850% Matches the consensus meanThe base case assumes OPKO successfully stabilizes its core diagnostics business post-restructuring, achieving near-breakeven performance by late 2026. NGENLA gross profit share grows steadily but remains within guided ranges ($34M-$37M for FY2026). Early-stage pipeline assets advance through Phase 1 trials without major safety setbacks, while the company utilizes its cash reserves to fund R&D and execute opportunistic share buybacks under its authorized program. Bull CaseUpside scenario $8.5030% The bull case is driven by a faster-than-expected path to profitability in the diagnostics segment by mid-2026, combined with a strong commercial acceleration of NGENLA globally through partner Pfizer. Additionally, positive early-stage clinical data from ModeX's multispecific antibody programs could trigger substantial milestone payments from partners like Merck and Regeneron, unlocking significant non-dilutive funding and validating the platform. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |